Compare Ascendis Pharma A/S (ASND) vs Stitch Fix Inc (SFIX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Stitch Fix Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Stitch Fix Inc trades at $3.57 (market cap $475.00M). The key difference: Ascendis Pharma A/S is far larger — about 37.3× Stitch Fix Inc's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Stitch Fix Inc nearer its low. Which is the better fit depends on your goals.
| ASND | SFIX | |
|---|---|---|
Market Cap | $17.74B | $475.00M |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $5.83 |
52-Week Low | $163.32 | $3.06 |
Enterprise Value | $18.11B | $362.71M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Stitch Fix (SFIX) trades at $3.56, up 1.14% today, showing signs of a potential turnaround despite technical bearish signals. The company has demonstrated improving fundamentals with three consecutive quarterly earnings beats and narrowing losses, while revenue has stabilized around $1.3 billion. Recent news highlights AI-driven personalization initiatives and growing client spending, though the stock remains near historic lows with a bearish technical outlook.
The outlook suggests cautious optimism as SFIX executes its turnaround strategy, with analyst consensus pointing to 33% upside potential. Key risks include ongoing net losses, competitive pressures in online retail, and execution challenges in maintaining client growth momentum. The stock presents a high-risk opportunity for investors betting on the company's AI-driven personalization strategy and margin improvement trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Stitch Fix Inc
Stitch Fix Inc offers personal style service for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandises with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types and price points including Women's, Petite, Maternity, Men's and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry and handbags, and sells merchandise across various range of price points.
Read more on SFIX →
